| Literature DB >> 29032341 |
Abhishek Gupta1, Ashok Kumar2, Durgesh Kumar3, Shiv Nandan4, Kripa Shankar1, Salil Varshney3, Sujith Rajan3, Ankita Srivastava3, Sanchita Gupta3, Sanjeev Kanojiya4, T Narender5, Anil Nilkanth Gaikwad6.
Abstract
Natural products have always fascinated mankind for their miraculous properties. Eclipta alba (E. alba), a medicinal herb has long been used in traditional medicine for curing several pathologies. It has been shown to have anti-diabetic effect as well as hepato-protective activity. Here, in order to address metabolic derangements, the study was designed to evaluate the efficacy of E. alba and its fractions in adipogenesis inhibition and dyslipidemia. Of the crude extract and fractions screened, ethyl acetate fraction of E. alba inhibited adipocyte differentiation in 3T3-L1 pre-adipocytes and hMSC derived adipocytes. It inhibited mitotic clonal expansion and caused cell cycle arrest in G1 and S phase as suggested by western blot analysis and flow cytometry. It was also shown to have lipolytic effects. Oral administration of ethyl acetate fraction of E. alba to hamsters unveiled its anti-adipogenic as well as anti-dyslipidemic activity in-vivo. Mass spectrometry analysis of ethyl acetate fraction confirmed the presence of several bioactive components, projecting it as an effective phytopharmaceutical agent. In conclusion, ethyl acetate fraction of E. alba possesses potent anti-adipogenic as well as anti-dyslipidemic activity and could be projected as an herbal formulation towards obesity.Entities:
Keywords: 3T3-L1 adipocyte; Adipogenesis; Dyslipidemia
Mesh:
Substances:
Year: 2017 PMID: 29032341 DOI: 10.1016/j.biopha.2017.10.002
Source DB: PubMed Journal: Biomed Pharmacother ISSN: 0753-3322 Impact factor: 6.529